---
title: "Top 18 mid-cap gainers last week include Ascentage Pharma (AAPG) up 38.35% and Ardagh Metal Packaging (AMBP) up 38.66%."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/239241465.md"
description: "Last week, mid-cap stocks Ascentage Pharma (AAPG) and Ardagh Metal Packaging (AMBP) saw significant gains of 38.35% and 38.66%, respectively. Ascentage Pharma is set to present data from two clinical studies at the 2025 ASCO Annual Meeting, focusing on its key assets Lisaftoclax and Alrizomadlin. Meanwhile, Ardagh Metal Packaging reported strong year-over-year growth in first-quarter adjusted EPS and revenue, prompting an upward adjustment of its FY25 adjusted EBITDA guidance."
datetime: "2025-05-08T02:42:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/239241465.md)
  - [en](https://longbridge.com/en/news/239241465.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/239241465.md)
---

# Top 18 mid-cap gainers last week include Ascentage Pharma (AAPG) up 38.35% and Ardagh Metal Packaging (AMBP) up 38.66%.

These eight mid-cap stocks demonstrated notable performance in the previous week. Ascentage Pharma Group Internat (NASDAQ: AAPG) observed a significant 38.35% surge in its stock price. The company is set to disclose data from two clinical studies at the 2025 ASCO Annual Meeting, presenting oral information regarding its key assets Lisaftoclax and Alrizomadlin. Ardagh Metal Packaging (NYSE: AMBP) saw a 38.66% increase in its shares following the report of year-over-year growth in first-quarter adjusted EPS results and revenue results surpassing expectations. In addition, the company adjusted its FY25 adjusted EBITDA guidance upwards. For more details, refer to the full article on Benzinga.com.

### Related Stocks

- [AAPGV.US](https://longbridge.com/en/quote/AAPGV.US.md)
- [AAPG.US](https://longbridge.com/en/quote/AAPG.US.md)

## Related News & Research

- [Ascentage Pharma corrects AGM date tied to RSU, option grant mandate to May 19, 2025](https://longbridge.com/en/news/292530336.md)
- [Ascentage Pharma Showcases Broad Leukemia Data for Olverembatinib and Lisaftoclax at EHA2026](https://longbridge.com/en/news/289705908.md)
- [Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Sees Significant Growth in Short Interest](https://longbridge.com/en/news/292362627.md)
- [Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026 | AAPG Stock News](https://longbridge.com/en/news/283571677.md)
- [Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 4.6%  - Here's Why](https://longbridge.com/en/news/294725472.md)